Sanofi sees stand-alone Japan generics biz complementing JV
This article was originally published in Scrip
Executive Summary
Reflecting its broader interests in the sector around the globe, Sanofi will independently enter the Japanese generic market later this year with the launch of versions of the antihypertensive valsartan (Novartis's Diovan) and zoledronic acid (Novartis's Zometa).